Article
Immunology
Rui Zheng, Yuankun Chen, Yiting Zhang, Sixin Liang, Xiaojuan Zhao, Yiyi Wang, Pengju Wang, Ruotong Meng, Angang Yang, Bo Yan
Summary: Our study explores the effect of low-affinity CARs using humanized scFvs on the function of CAR-T cells. We find that moderately reducing the affinity of CARs can maintain anti-tumor efficacy and improve the safety of CAR therapy both in vitro and in vivo. In addition, T cells expressing the VL domain only antibody show long-lasting tumor elimination capability and lower cytokine levels.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Peng Zhang, Yang Zhang, Nan Ji
Summary: Glioblastoma (GBM) is a deadly brain cancer with limited efficacy of standard treatments, necessitating the development of new therapies. Chimeric antigen receptor T (CAR-T) cell immunotherapy has shown success in hematological malignancies, but has not yet yielded promising results in GBM. CAR-T cell therapy for GBM faces challenges including tumor heterogeneity, immunosuppressive microenvironment, and cell persistence.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Sophia Stock, Anna-Kristina Kluever, Stefan Endres, Sebastian Kobold
Summary: Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in treating specific hematological malignancies. However, many patients do not respond or relapse after treatment. Strategies such as combining CAR T cells with other treatments and using clinically approved compounds have been investigated to improve this therapy.
Review
Immunology
Bu-Fan Xiao, Jing-Tao Zhang, Yu-Ge Zhu, Xin-Run Cui, Zhe-Ming Lu, Ben-Tong Yu, Nan Wu
Summary: CAR-T cell therapy has shown significant clinical responses in hematological malignancies and is now being evaluated for treating solid tumors. Challenges in using CAR-T cells for lung cancer treatment include on-target, off-tumor toxicity, scarcity of tumor-specific antigen targets, T cell exhaustion, and low immune cell infiltration levels. Advances in tumor immunology and cell product manufacturing are driving the clinical translation of CAR-T cell therapy for lung cancer.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Sophia Stock, Anna-Kristina Kluever, Luisa Fertig, Vivien D. Menkhoff, Marion Subklewe, Stefan Endres, Sebastian Kobold
Summary: The clinical application of CAR T-cell therapy has revolutionized the treatment options for certain terminally ill patients with blood-borne cancers. However, the therapy can lead to severe toxicities, and efforts are being made to better control CAR T-cell activity and manage its associated side effects through various strategies and mechanisms.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Clinical Neurology
Lisa Feldman, Christine Brown, Behnam Badie
Summary: CAR T-cell therapy, utilizing genetically engineered cells from patients to target tumor cells, has emerged as a promising strategy for treating GBM. Ongoing clinical trials are exploring the potential of this approach to combat the challenges associated with GBM treatment.
Review
Oncology
Mahasha P. J. Perera, Patrick B. Thomas, Gail P. Risbridger, Renea Taylor, Arun Azad, Michael S. Hofman, Elizabeth D. Williams, Ian Vela
Summary: This review discusses the role of CAR-T cell therapy in men with metastatic castrate-resistant prostate cancer. Prostate cancer is the most commonly diagnosed solid-organ cancer in males worldwide. Men with metastatic castrate-resistant prostate cancer have limited treatment options, and current therapies are not curative. CAR-T cell therapy has shown success in the treatment of treatment-resistant hematological malignancies, and there are ongoing studies investigating its utility in solid tumors. However, preliminary clinical trials in men with prostate cancer have had limited efficacy, indicating the need for further research to enhance understanding and translation of this therapy.
Review
Medicine, Research & Experimental
Yuxi Luo, Guiqin Song, Shichu Liang, Feifei Li, Kang Liu
Summary: CAR-modified T-cells, a novel cancer immunotherapy, target specific surface antigens on tumor cells through genetic engineering. While showing notable efficacy in hematological tumor treatment, challenges exist in treating solid tumors, along with specific side effects associated with CAR T-cell therapy.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Review
Biochemical Research Methods
Cuilin Zhang, Qiuyu Zhuang, Jingfeng Liu, Xiaolong Liu
Summary: Synthetic biology is an interdisciplinary research area that uses engineering principles to design and construct biological systems for practical applications. Chimeric antigen receptor (CAR) T cells, as one of the most successful clinical applications of synthetic biology, have shown tremendous success in treating blood malignancies. However, there are still limitations to CAR T cell therapy, hence the need for innovative CAR design becomes urgent.
ACS SYNTHETIC BIOLOGY
(2022)
Article
Oncology
Nattaporn Phanthaphol, Chalermchai Somboonpatarakun, Kwanpirom Suwanchiwasiri, Thaweesak Chieochansin, Jatuporn Sujjitjoon, Sopit Wongkham, John Maher, Mutita Junking, Pa-thai Yenchitsomanus
Summary: CAR T cell therapy has shown efficacy in hematologic malignancies, but further investigation is needed for its application in solid tumors. The selection of target antigens highly expressed in cancer cells but not normal cells is crucial for successful immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Rui Mao, Mohamed S. Hussein, Yukai He
Summary: This article reviews the factors that affect the activation, effector function, in vivo persistence, and antitumor effects of chimeric antigen receptor T cells (CAR-T). These factors include T cell subsets, CAR design, expression promoters and delivery vectors, and CAR-T production process. The comparison between CAR signaling and TCR activation is also discussed. The article provides insights into CAR design for solid tumors, focusing on strategies to improve CAR-T tumor infiltration and survival in the hostile tumor microenvironment.
EXPERT REVIEWS IN MOLECULAR MEDICINE
(2022)
Article
Immunology
Bilge Debelec-Butuner, Oliver Quitt, Sophia Schreiber, Frank Momburg, Karin Wisskirchen, Ulrike Protzer
Summary: Despite the availability of a prophylactic vaccine, many people still die from hepatitis B virus (HBV)-related liver disease. Current antiviral therapies are not curative, so new strategies are urgently needed. This study explores the use of bi- and trispecific T-cell engager antibodies as an alternative treatment for HBV.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Jingting Min, Chirong Long, Lu Zhang, Jiakang Duan, Honglian Fan, Fei Chu, Zhenghong Li
Summary: Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy, and CAR-T cell therapy targeting c-Met shows potential as a therapeutic strategy. In vitro and in vivo experiments demonstrated that c-Met CAR-T cells exhibit enhanced cytotoxicity against NSCLC cells.
Review
Oncology
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, Gerard M. J. Bos, Wilfred T. V. Germeraad
Summary: NK cells, especially CAR-NK cells, play a crucial role in cancer treatment. Advances in CAR-NK technology show promising potential in efficiently targeting cancer cells with reduced side effects. These developments contribute to improving cancer treatment strategies.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Wenwen Wei, Dong Yang, Xi Chen, Dandan Liang, Liqun Zou, Xudong Zhao
Summary: This review summarizes the characteristics of non-B-cell acute leukemia and the efficacy and challenges of CAR-T cell therapy in treating this type of leukemia.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Giovanni Gambi, Elisabetta Di Simone, Veronica Basso, Luisa Ricci, Rui Wang, Akanksha Verma, Olivier Elemento, Maurilio Ponzoni, Giorgio Inghirami, Laura Icardi, Anna Mondino
Article
Biophysics
Jan Styczynski, Gloria Tridello, Linda Koster, Simona Iacobelli, Anja van Biezen, Steffie van der Werf, Malgorzata Mikulska, Lidia Gil, Catherine Cordonnier, Per Ljungman, Diana Averbuch, Simone Cesaro, Rafael de la Camara, Helen Baldomero, Peter Bader, Grzegorz Basak, Chiara Bonini, Rafael Duarte, Carlo Dufour, Jurgen Kuball, Arjan Lankester, Silvia Montoto, Arnon Nagler, John A. Snowden, Nicolaus Kroeger, Mohamad Mohty, Alois Gratwohl
BONE MARROW TRANSPLANTATION
(2020)
Article
Chemistry, Multidisciplinary
Anna Maria Gasparri, Angelina Sacchi, Veronica Basso, Filippo Cortesi, Massimo Freschi, Eltjona Rrapaj, Matteo Bellone, Giulia Casorati, Paolo Dellabona, Anna Mondino, Angelo Corti, Flavio Curnis
Article
Multidisciplinary Sciences
Efthymia Vokali, Shann S. Yu, Sachiko Hirosue, Marcela Rincon-Restrepo, Fernanda Duraes, Stefanie Scherer, Patricia Corthesy-Henrioud, Witold W. Kilarski, Anna Mondino, Dietmar Zehn, Stephanie Hugues, Melody A. Swartz
NATURE COMMUNICATIONS
(2020)
Review
Immunology
Anna Mondino, Teresa Manzo
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Oncology
Giovanni Germano, Steve Lu, Giuseppe Rospo, Simona Lamba, Benoit Rousseau, Sonia Fanelli, Denise Stenech, Dung T. Le, John Hays, Maria Grazia Totaro, Vito Amodio, Rosaria Chila, Anna Mondino, Luis A. Diaz, Federica Di Nicolantonio, Alberto Bardelli
Summary: The inactivation of beta-2 microglobulin (B2M) does not reduce the efficacy of immune checkpoint inhibitors (ICPis) in MMRd tumors, and a unique role for CD4(+) T cells in tumor rejection is identified.
Article
Medicine, Research & Experimental
Rosanna Mezzapelle, Francesco De Marchis, Chiara Passera, Manuela Leo, Francesca Brambilla, Federica Colombo, Maura Casalgrandi, Alessandro Preti, Samuel Zambrano, Patrizia Castellani, Riccardo Ertassi, Marco Silingardi, Francesca Caprioglio, Veronica Basso, Renzo Boldorini, Angelo Carretta, Francesca Sanvito, Ottavio Rena, Anna Rubartelli, Lina Sabatino, Anna Mondino, Massimo P. Crippa, Vittorio Colantuoni, Marco E. Bianchi
Summary: Enhancing antitumor immunity is a powerful strategy in cancer treatment, involving the release of DAMPs and interfering with the CD47 signal to induce T-cell immune responses. Additionally, CXCR4 activation can also flag tumor cells for immune recognition.
EMBO MOLECULAR MEDICINE
(2021)
Article
Biotechnology & Applied Microbiology
Angelo Corti, Angelina Sacchi, Anna Maria Gasparri, Matteo Monieri, Giulia Anderluzzi, Barbara Colombo, Alessandro Gori, Anna Mondino, Flavio Curnis
Summary: Gold nanospheres tagged with isoDGR peptides can efficiently deliver pro-inflammatory cytokines to tumor vasculature. Bifunctional or trifunctional nanoparticles loaded with TNF and/or IL12, along with isoDGR peptides, show anti-cancer effects in a mouse model of fibrosarcoma by delaying tumor growth and enhancing doxorubicin efficacy without increasing toxicity. Mechanistic studies suggest that these nanoparticles can improve doxorubicin penetration in tumors and cause vascular damage.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Review
Immunology
Ken Maes, Anna Mondino, Juan Jose Lasarte, Xabier Agirre, Karin Vanderkerken, Felipe Prosper, Karine Breckpot
Summary: Cancer cells can evade the immune system through epigenetic alterations, but epigenetic modulating agents have the potential to restore immunological fitness and overcome peripheral tolerance to transformed cells. By acting on both cancer cells and immune cells, EMAs represent interesting strategies for combinatorial therapies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Francesco Manfredi, Danilo Abbati, Beatrice Claudia Cianciotti, Lorena Stasi, Alessia Potenza, Eliana Ruggiero, Zulma Magnani, Erica Carnevale, Matteo Doglio, Maddalena Noviello, Elena Tassi, Chiara Balestrieri, Silvia Buonanno, Francesca Clemente, Claudia De Lalla, Maria Pia Protti, Anna Mondino, Giulia Casorati, Paolo Dellabona, Chiara Bonini
Summary: The article introduced a new tool called CytoChain for analyzing dynamic and complex flow cytometry samples to help researchers identify stem-like memory cells (T-SCM) suitable for adoptive T-cell therapy. By applying CytoChain, researchers successfully discovered a previously unidentified cell feature with superior expansion potential, providing support for new immunophenotypes in immunotherapy and patient immunomonitoring.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Review
Immunology
Arianna Pocaterra, Marco Catucci, Anna Mondino
Summary: This review highlights the benefits of combining adoptive T cell therapy (ACT) with conventional chemo and/or radiotherapy for the treatment of solid tumors. Despite the challenges such as sub optimal T cell engraftment, tumor infiltration, poor tumor antigenicity/immunogenicity, and immunosuppression, recent advances show that these concomitant treatments can help overcome these barriers and promote a more favorable microenvironment for tumor eradication.
CURRENT OPINION IN IMMUNOLOGY
(2022)
Article
Ophthalmology
Romina Mayra Lasagni Vitar, Filippo Bonelli, Ayca Atay, Francesca Triani, Philippe Fonteyne, Elisabetta Di Simone, Paolo Rama, Anna Mondino, Giulio Ferrari
Summary: The study evaluated the effect of the NK1R antagonist Fosaprepitant in a pre-clinical model of ocular GVHD, showing that Fosaprepitant significantly reduced immune cell infiltration and decreased the expression of inflammatory mediators, providing a novel therapeutic approach for ocular GVHD.
EXPERIMENTAL EYE RESEARCH
(2021)
Article
Biology
G. Pozzi, B. Grammatica, L. Chaabane, M. Catucci, A. Mondino, P. Zunino, P. Ciarletta
Summary: T cell therapy has emerged as a promising approach for treating solid cancers. This study presents a mathematical model that accurately predicts the behavior of T cells in mouse prostate adenocarcinoma, demonstrating the potential of activating tumor-associated vessels to enhance therapeutic effects. The diffusion-interface mathematical model provides insights for optimizing immunotherapy against cancer.
JOURNAL OF THEORETICAL BIOLOGY
(2022)
Article
Immunology
Lien De Beck, Robin Maximilian Awad, Veronica Basso, Noelia Casares, Kirsten De Ridder, Yannick De Vlaeminck, Alessandra Gnata, Cleo Goyvaerts, Quentin Lecocq, Edurne San Jose-Eneriz, Stefaan Verhulst, Ken Maes, Karin Vanderkerken, Xabier Agirre, Felipe Prosper, Juan Jose Lasarte, Anna Mondino, Karine Breckpot
Summary: Combination therapies hold promise for improving the clinical response rates of malignant skin cancer, particularly melanoma. In this study, a dual inhibitor of histone methyltransferase G9a and DNA methyltransferases (DNMTs) was found to induce tumor cell cycle arrest and apoptosis, promote immune cell infiltration, and increase the efficacy of TCR-redirected T cell and dendritic cell vaccination in a preclinical melanoma model.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Ophthalmology
Filippo Bonelli, Romina Mayra Lasagni Vitar, Francesco Giorgio Merlo Pich, Philippe Fonteyne, Paolo Rama, Anna Mondino, Giulio Ferrari
Summary: This study aimed to investigate corneal endothelial morphology and the expression of neurokinin-1 receptor (NK1R) in ocular graft-versus-host disease (oGVHD) using a mouse model. The results showed that oGVHD led to a reduction in corneal endothelial cell number and an increase in NK1R expression.
EXPERIMENTAL EYE RESEARCH
(2022)